Article
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Arteriosclerosis, thrombosis, and vascular biology - 1 May 2002
Juhan-Vague I, Morange P E, Aubert H, Henry M, Aillaud M F, Alessi M C, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries S E
Abstract excerpt
The thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis that decreases plasminogen binding to the fibrin surface. The plasma TAFI concentration is almost entirely genetically determined. We investigated whether plasma TAFI levels and polymorphisms located in the TAFI gene could constitute risk markers of myocardial infarction (MI). Plasma TAFI antigen (Ag) levels...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.